Skip to content

A clinical study on efficacy and safety of LingQiShen Extracts in treating type 2 diabetic patients with Syndrome QiYinLiangXu

A randomized, double-blinded, placebo-controlled and prospective study of eveluating the efficacy and safety of LingQiShen Extracts in the treatment of type 2 diabetic patients with Syndrome QiYinLiangXu

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16008737
Enrollment
Unknown
Registered
2016-06-28
Start date
2016-07-10
Completion date
Unknown
Last updated
2017-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

LinQiShen:LinQiShen
Control:placebo

Sponsors

Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. type 2 diabet mellitus and accord with TCM Syndrome Type of qiyinliangxu Type; 2. Aged from 18 to 65 years old; 3. Have the alimentary control ,cinesiotherapy or alimentary control, cinesiotherapy with the antidiabetic drugs at the same time,and the treatment plan stabilized more than 3 months; HbA1c 7% to 9%; 4. Agree with all the contracts.

Exclusion criteria

Exclusion criteria: 1. Gestation period or suckling period women; 2. The patients who have serious heart, brain, liver, kidney complications , other serious primary diseases or mental disease; 3. Allergic constitution (refers to more than two kinds of drugs or food allergies) or known to the test of drug ingredients allergy; 4. The patients who have acute metabolic disorders as diabetic ketoacidosis or infction. 5. Alt exceeds the upper limit of the normal value of 1.5 times; 6. Cr exceeds normal value; 7. To be not able to follow the doctor's advice; 8. Patients participating in other drugs clinical trials.

Design outcomes

Primary

MeasureTime frame
HemoglobinA1c;Syndrome Index;

Secondary

MeasureTime frame
fasting plasma glucose;2 hour postprandial glucose;homa2 IR;blood lipids;

Countries

China

Contacts

Public ContactTAO Feng

Shuguang Hospital affiliated to Shanghai University of TCM

feng.tao@shsgyy-endo.cn+86 21 20256392

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026